Klinická farmakologie a farmacie – 4/2020

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2020; 34(4): 168–170 / www.klinickafarmakologie.cz 170 HLAVNÍ TÉMA Liraglutid u diabetikov v štúdii LEADER – nachádzame benefit u chorých so srdcovým zlyhávaním? cardiovascular and renal events in type 2 diabets. N Engl J Med 2017; 377: 644–657. 6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and car‑ diovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357. 7. Sun F, Wu S, Guo S, et al. Effect of GLP-1 receptor agonis‑ ts on waist circumference among type 2 diabetes patients: a systematic review and network meta‑analysis. Endocrine 2015; 48: 794–803. 8. Holman RR, Bethel MA, Mentz RJ et al. Effects of once­ ‑weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 2017; 377: 1228–1239. 9. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardi‑ ovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844. 10. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semag‑ lutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841–851. 11. Hernandez AF, Green JB, Janmohamed S, et al. Albiglu‑ tide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double‑blind, randomised placebo‑controlled trial. Lan‑ cet 2018; 392: 1519–1529. 12. Marso SP, Daniels GH, Brown‑Frandsen K, et al. Liraglu‑ tide and cardiovascular outcomes in type 2 diabets. N Engl J Med 2016; 375: 311–322. 13. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in pati‑ ents with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–2257. 14. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial. Lan‑ cet 2019; 394: 121–130. 15. Kristensen sL, Rorth R, Jhund PS. et al. Cardiovascular mortality, and kidney outcomes with GLP-1 receptor agoni‑ sts in patients with type 2 diabetes: a systematic review and meta‑analysis of cardiovascular outcome trials. Lancet Dia‑ betes Endocrinol 2019; 7: 776–785. 16. Zhang JY, Wang XY, Wang X. Effects of liraglutide on he‑ modynamic parameters in patients with heart failure. Onco‑ target 2017; 8: 62693–62702. 17. Arturi F, Succurro E, Miceli S, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chro‑ nic heart failure. Endocrine 2017; 57: 464–473. 18. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with adva‑ ced heart failure and reduced ejection fraction: a randomi‑ zed clinical trial. JAMA 2016; 316: 500–508. 19. Jorsal A, Kistorp C, Holmager P, et al. Ef fect of lirag‑ lutide, a glucagon‑like peptide-1 analogue, on left ven‑ tricular function in stable chronic heart failure patients with and without diabetes ((LIVE)-a multicentre, double­ ‑blind, randomised, placebo‑controlled trial. Eur J Heart Fail 2017; 19: 69–77. 20. Marso SP, Baeres FNM, Bain SC, et al. Ef fects of liraglu‑ tide on cardiovascular outcomes in patients with diabe‑ tes with or without heart failure. J Am Coll Cardiol 2020; 75: 1128–1141. 21. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guide‑ lines on diabetes, pre‑diabetes, and cardiovascular disea‑ ses developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323. 22. Fitchett D, Butler J, van de Borne P, et al. Effects of em‑ pagliflozin on risk for cardiovascular death and heart failu‑ re hospitalization across the spectrum of heart failure risk in the EMPA‑REG OUTCME trial. Eur Heart J 2018; 39: 363–370. 23. RadholmK, FigtreeG, Perkovic V, et al. Canagliflozin andheart failure in type 2 diabetesmellitus. Circulation 2018; 138: 458–468. 24. Kato ET, Silverman MG, Mosenzon O, et al. Effect of da‑ pagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; 139: 2528–2536. 25. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxag‑ liptin, and diabetes mellitus: observations from the SAVOR­ ‑TIMI53 randomized trial. Circulation 2014; 130: 1579–1588. 26. Verma S, Goldenberg RM, Bhatt DL, et al. Dipeptidyl pep‑ tidase-4 inhibitors and the risk of heart failure: a systematic review and meta‑analysis. CMAJ Open 2017; 5: E152–E177. 27. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitag‑ liptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242. 28. McGuire DK, Alexander JH, Johansen OE, et al. Linaglip‑ tin effects on heart failure and related outcomes in indivi‑ duals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 2019; 139: 351–361.